Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias

Experimental Neurology

Volumn 225, Issue 2, 2010, Pages 408-415

  Malmlöf, Torun ^a   Rylander, Daniella ^b   Alken, Rudolf Giesbert ^c   Schneider, Frank ^d   Svensson, Torgny H ^a   Cenci, M Angela ^b   Schilström, Björn ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c BiRDS Pharma GmbH   (Germany)

^d CDRD Berolina AB ^*  (Germany)

Author keywords

6 OHDA; Behavior; Deuterium; Dyskinesia; Enzyme; Isotope; L DOPA; Parkinson's disease; Pharmacokinetics; Rat

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE; ISOTOPE; LEVODOPA; LEVODOPA D 3; OXIDOPAMINE; UNCLASSIFIED DRUG; DOPAMINE TRANSPORTER; TYROSINE 3 MONOOXYGENASE;

AKINESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CIRCLING BEHAVIOR; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE CONTROL; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DYSKINESIA; FEMALE; LOCOMOTION; LOW DRUG DOSE; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; RISK REDUCTION; STRUCTURE ACTIVITY RELATION; ANALYSIS OF VARIANCE; ANIMAL; AUTORADIOGRAPHY; BRAIN; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; IMMUNOHISTOCHEMISTRY; METABOLISM; MOTOR ACTIVITY; NONPARAMETRIC TEST; PARKINSON DISEASE, SECONDARY; ROTAROD TEST; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANIMALS; AUTORADIOGRAPHY; BRAIN; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DYSKINESIA, DRUG-INDUCED; IMMUNOHISTOCHEMISTRY; LEVODOPA; MOTOR ACTIVITY; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; ROTAROD PERFORMANCE TEST; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TYROSINE 3-MONOOXYGENASE;

EID: 77956427251     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.07.018     Document Type: Article

References (37)

1. Bibbiani F., Costantini L.C., Patel R., Chase T.N. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp. Neurol. 2005, 192:73-78.
2. Blake M.I., Crespi H.L., Katz J.J. Studies with deuterated drugs. J. Pharm. Sci. 1975, 64:367-391.
3. Blanchet P.J., Calon F., Martel J.C., Bedard P.J., Di Paolo T., Walters R.R., Piercey M.F. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J. Pharmacol. Exp. Ther. 1995, 272:854-859.
4. Cenci M.A., Lundblad M. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J. Neurochem. 2006, 99:381-392.
5. Cenci M.A., Lundblad M. Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr. Protoc. Neurosci. 2007, 25. Chapter 9, Unit 9.
6. Cenci M.A., Whishaw I.Q., Schallert T. Animal models of neurological deficits: how relevant is the rat?. Nat. Rev. Neurosci. 2002, 3:574-579.
7. Dufner D., Previs S.F. Measuring in vivo metabolism using heavy water. Curr. Opin. Clin. Nutr. Metab. Care 2003, 6:511-517.
8. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C.W., Tanner C., Marek K. Levodopa and the progression of Parkinson's disease. N Engl J. Med. 2004, 351:2498-2508.
9. Floresco S.B., West A.R., Ash B., Moore H., Grace A.A. Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat. Neurosci. 2003, 6:968-973.
10. Fozard J.R., Palfreyman M.G., Robin M., Zreika M. Selective inhibition of monoamine oxidase type B by MDL 72145 increases the central effects of L-dopa without modifying its cardiovascular effects. Br. J. Pharmacol. 1986, 87:257-264.
11. Goetz C.G., Poewe W., Rascol O., Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov. Disord. 2005, 20:523-539.
12. Heikkila R.E., Cabbat F.S., Manzino L., Duvoisin R.C. Potentiation by deprenil of 1-dopa induced circling in nigral-lesioned rats. Pharmacol. Biochem. Behav. 1981, 15:75-79.
13. Jones P.J., Leatherdale S.T. Stable isotopes in clinical research: safety reaffirmed. Clin. Sci. (Lond) 1991, 80:277-280.
14. Klein P.D., Klein E.R. Stable isotopes: origins and safety. J. Clin. Pharmacol. 1986, 26:378-382.
15. Koletzko B., Sauerwald T., Demmelmair H. Safety of stable isotope use. Eur. J. Pediatr. 1997, 156(Suppl 1):S12-S17.
16. Kushner D.J., Baker A., Dunstall T.G. Pharmacological uses and perspectives of heavy water and deuterated compounds. Can. J. Physiol. Pharmacol. 1999, 77:79-88.
17. Lindgren H.S., Rylander D., Ohlin K.E., Lundblad M., Cenci M.A. The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. Behav. Brain Res. 2007, 177:150-159.
18. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2002, 15:120-132.
19. Lundblad M., Vaudano E., Cenci M.A. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J. Neurochem. 2003, 84:1398-1410.
20. Malmlöf T., Svensson T.H., Schilstrom B. Altered behavioural and neurochemical profile of L-DOPA following deuterium substitutions in the molecule. Exp. Neurol. 2008, 212:538-542.
21. Marin C., Rodriguez-Oroz M.C., Obeso J.A. Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?. Exp. Neurol. 2006, 197:269-274.
22. Miller S.M., Klinman J.P. Magnitude of intrinsic isotope effects in the dopamine beta-monooxygenase reaction. Biochemistry 1983, 22:3091-3096.
23. Moses D., Gross A., Finberg J.P. Rasagiline enhances L-DOPA-induced contralateral turning in the unilateral 6-hydroxydopamine-lesioned guinea-pig. Neuropharmacology 2004, 47:72-80.
24. Nutt J.G. Motor fluctuations and dyskinesia in Parkinson's disease. Parkinsonism Relat. Disord. 2001, 8:101-108.
25. Olanow C.W., Obeso J.A., Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 2006, 5:677-687.
26. Olanow C.W., Stern M.B., Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 2009, 72:S1-S136.
27. Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., Fisone G., Cenci M.A., Calabresi P. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat. Neurosci. 2003, 6:501-506.
28. Rylander D., Recchia A., Mela F., Dekundy A., Danysz W., Cenci M.A. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J. Pharmacol. Exp. Ther. 2009, 330:227-235.
29. Sanderson K. Big interest in heavy drugs. Nature 2009, 458:269.
30. Schrag A., Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000, 123(Pt 11):2297-2305.
31. Sharma J.C., Macnamara L., Hasoon M., Vassallo M., Ross I. Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade). Parkinsonism Relat. Disord. 2006, 12:499-505.
32. Sharma J.C., Ross I.N., Rascol O., Brooks D. Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight. Eur. J. Neurol. 2008, 15:493-496.
33. Stefanova N., Lundblad M., Tison F., Poewe W., Cenci M.A., Wenning G.K. Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy). Neurobiol. Dis. 2004, 15:630-639.
34. Syed N., Murphy J., Zimmerman T., Mark M.H., Sage J.I. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov. Disord. 1998, 13:336-338.
35. Winkler C., Kirik D., Bjorklund A., Cenci M.A. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 2002, 10:165-186.
36. Yu P.H., Bailey B.A., Durden D.A., Boulton A.A. Stereospecific deuterium substitution at the alpha-carbon position of dopamine and its effect on oxidative deamination catalyzed by MAO-A and MAO-B from different tissues. Biochem. Pharmacol. 1986, 35:1027-1036.
37. Yu P.H., Kazakoff C., Davis B.A., Boulton A.A. Deuterium isotope effect on the enzymatic oxidation of dopamine and serotonin. Biochem. Pharmacol. 1982, 31:3697-3698.